FDA 483 - Allergan Pharmaceuticals Ireland - January 30, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Allergan Pharmaceuticals Ireland Unlimited, a drug product manufacturer in Westport, Ireland, was cited for multiple deficiencies during an FDA inspection. The observations included inadequate visual inspection rejection limits, insufficient laboratory test procedures for endotoxin, and a lack of cleaning validation for indirect product contact parts. Further issues were noted in environmental monitoring for aseptic processing areas and shipping validation for samples.
ID · 621f52b2-bbcb-409b-ab8f-70a89c613fd3